Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases

Pituitary

Volumn 16, Issue 3, 2013, Pages 354-362

  Burton, Tanya ^a   Le Nestour, Elisabeth ^b   Bancroft, Tim ^a   Neary, Maureen ^c  

^a OPTUM   (United States)

^b PharmaNet/i3   (France)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Acromegaly; Bromocriptine; Cabergoline; Comorbidities; Lanreotide; Octreotide; Pegvisomant; Somatostatin analogues; Treatment patterns

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; OCTREOTIDE; PEGVISOMANT;

ACROMEGALY; ADULT; ARTICLE; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG USE; ENDOCRINE SURGERY; FEMALE; HEALTH CARE PLANNING; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNITED STATES;

EID: 84881374531     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0432-6     Document Type: Article

References (17)

1. American Association of Clinical Endocrinologists (2004) Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract 10(3):213-225
2. Lugo G, Pena L, Coriddo F (2012) Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol 540398:10
3. Biermasz N, Pereira A, Smit J et al (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complications cause reduced quality of life. J Clin Endocrinol Metabol 90:2731-2739
4. Melmed S (2006) Acromegaly: medical progress. N Engl J Med 355:2558-2573
5. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metabol 94(5):1509-1517
6. Ben-Shlomo A, Sheppard MC, Stephens JM (2011) Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14:284-294
7. Clay RN (2003) Cardiovascular function in acromegaly. Endocr Rev 24(3):272-277
8. Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. Pituitary 2:29-41
9. Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum level of GH and IGF-1 on mortality in acromegaly. Eur J Endocrinol 159:89-95
10. Reid TJ, Post KD, Bruce JN et al (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol 72(2):203-208
11. Cordero RA, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102-152
12. Quan H et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130-1139
13. Chanson P, Salenave S (2008) Acromegaly: review. Orphanet J Rare Dis 3:17
14. Davi' MV, Carbonare DL, Giustina A, Ferrari M, Frigo A, Lo Cascio V, Francia G (2008) Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 159:533-540
15. Minniti G, Esposito V, Piccirilli M, Fratticci A, Santoro A, Jaffrain-Rea ML (2005) Diagnosis and management of pituitary tumours in the elderly: a review based on personal experience and evidence of literature. Eur J Endocrinol 153:723-735
16. Bandgar TR, Sarathi V, Shivane V, Bansode N, Menon PS, Shah NS (2010) The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly. J Postgrad Med 56(1):7-11
17. Ben-Shlomo A, Melmed S (2008) Acromegaly. Endocrinol Metab Clin N Am 37(1):101-viii. doi: 10.1016/j.ecl.2007.10.002